315 related articles for article (PubMed ID: 16211218)
81. Pure intravascular recurrence of CD5-positive diffuse large B-cell lymphoma primarily arising from the nasal cavities.
Kano R; Masaie H; Hino A; Yasuoka H; Nagata S; Ishikawa J; Nakatsuka SI
Diagn Pathol; 2018 Jul; 13(1):46. PubMed ID: 30041681
[TBL] [Abstract][Full Text] [Related]
82. Role of CD21 antigen in diffuse large B-cell lymphoma and its clinical significance.
Otsuka M; Yakushijin Y; Hamada M; Hato T; Yasukawa M; Fujita S
Br J Haematol; 2004 Nov; 127(4):416-24. PubMed ID: 15521918
[TBL] [Abstract][Full Text] [Related]
83. Diminished expression of CD19 in B-cell lymphomas.
Yang W; Agrawal N; Patel J; Edinger A; Osei E; Thut D; Powers J; Meyerson H
Cytometry B Clin Cytom; 2005 Jan; 63(1):28-35. PubMed ID: 15624204
[TBL] [Abstract][Full Text] [Related]
84. Altered N-glycosylation in CD45 and regulatory roles of altered N-glycosylation in galectin-1-induced growth inhibition in human diffuse large B cell lymphoma.
Suzuki O; Nozawa Y; Abe M
Oncol Rep; 2005 Jan; 13(1):109-14. PubMed ID: 15583810
[TBL] [Abstract][Full Text] [Related]
85. Cytogenetic analysis of de novo CD5-positive diffuse large B-cell lymphoma.
Kaneko H; Shimura K; Horiike S; Kuroda J; Matsumoto Y; Yokota S; Nishida K; Ohkawara Y; Taniwaki M
Asia Pac J Clin Oncol; 2011 Dec; 7(4):346-50. PubMed ID: 22151983
[TBL] [Abstract][Full Text] [Related]
86. Intravascular large B-cell lymphoma presenting with mass lesions in the central nervous system: a report of five cases.
Imai H; Kajimoto K; Taniwaki M; Miura I; Hatta Y; Hashizume Y; Watanabe M; Shiraishi T; Nakamura S
Pathol Int; 2004 Apr; 54(4):231-6. PubMed ID: 15028023
[TBL] [Abstract][Full Text] [Related]
87. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas.
Kluiver J; Poppema S; de Jong D; Blokzijl T; Harms G; Jacobs S; Kroesen BJ; van den Berg A
J Pathol; 2005 Oct; 207(2):243-9. PubMed ID: 16041695
[TBL] [Abstract][Full Text] [Related]
88. High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma.
Green TM; Nielsen O; de Stricker K; Xu-Monette ZY; Young KH; Møller MB
Am J Surg Pathol; 2012 Apr; 36(4):612-9. PubMed ID: 22314191
[TBL] [Abstract][Full Text] [Related]
89. De novo CD5-positive diffuse large B-cell lymphomas show high specificity for cyclin D2 expression.
Igawa T; Sato Y; Takata K; Iwaki N; Tanaka T; Asano N; Maeda Y; Orita Y; Nakamura N; Nakamura S; Yoshino T
Diagn Pathol; 2013 May; 8():81. PubMed ID: 23675804
[TBL] [Abstract][Full Text] [Related]
90. CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Bruton's Tyrosine Kinase Inhibition.
Cooper A; Tumuluru S; Kissick K; Venkataraman G; Song JY; Lytle A; Duns G; Yu J; Kotlov N; Bagaev A; Hodkinson B; Srinivasan S; Smith SM; Scott DW; Steidl C; Godfrey JK; Kline J
J Clin Oncol; 2024 Feb; 42(4):467-480. PubMed ID: 38079587
[TBL] [Abstract][Full Text] [Related]
91. Thymidine phosphorylase expression in B-cell lymphomas and its significance: a new prognostic marker?
Nie X; Clifford PM; Bhat R; Heintzelman R; Abraham M; Hou JS
Anal Quant Cytopathol Histpathol; 2013 Dec; 35(6):301-5. PubMed ID: 24617035
[TBL] [Abstract][Full Text] [Related]
92. [Sub-classification of diffuse large B-cell lymphoma by semi-quantification of the CD5 expression with flow cytometric analysis].
Manabe N; Yamaoka G; Ohnishi H; Arai T; Nakaishi H; Kajikawa T; Kubota Y; Tanaka T; Kitanaka A; Waki M; Kawakami K; Nagai M; Ishida T; Taminato T
Rinsho Byori; 2002 Sep; 50(9):906-11. PubMed ID: 12386970
[TBL] [Abstract][Full Text] [Related]
93. Analysis of the immunoglobulin heavy chain gene variable region of CD5-positive and -negative diffuse large B cell lymphoma.
Nakamura N; Kuze T; Hashimoto Y; Hara Y; Hoshi S; Sasaki Y; Shirakawa A; Sato M; Abe M
Leukemia; 2001 Mar; 15(3):452-7. PubMed ID: 11237070
[TBL] [Abstract][Full Text] [Related]
94. [Morphoimmunohistological differential diagnosis between Hodgkin's lymphoma with lymphoid prevalence and large B-cell lymphoma].
Kovrigina AM; Probatova NA
Arkh Patol; 2005; 67(4):10-6. PubMed ID: 16209291
[TBL] [Abstract][Full Text] [Related]
95. Benign CD10-positive T cells in reactive lymphoid proliferations and B-cell lymphomas.
Cook JR; Craig FE; Swerdlow SH
Mod Pathol; 2003 Sep; 16(9):879-85. PubMed ID: 13679451
[TBL] [Abstract][Full Text] [Related]
96. CD5-positive follicular lymphoma: prognostic significance of this aberrant marker?
Mayson E; Saverimuttu J; Cartwright K
Intern Med J; 2014 Apr; 44(4):417-22. PubMed ID: 24754692
[TBL] [Abstract][Full Text] [Related]
97. Immunophenotyping large B-cell lymphomas. Flow cytometric pitfalls and pathologic correlation.
Bertram HC; Check IJ; Milano MA
Am J Clin Pathol; 2001 Aug; 116(2):191-203. PubMed ID: 11488065
[TBL] [Abstract][Full Text] [Related]
98. [CD5-positive DLBCL: molecular basis and treatment strategies].
Miyazaki K
Rinsho Ketsueki; 2015 Aug; 56(8):1038-44. PubMed ID: 26345564
[TBL] [Abstract][Full Text] [Related]
99. [Clinicopathological features of de novo CD5-positive diffuse large B-cell lymphoma].
Fan Y; Dong L; OUYang BS; Xu HM; Zheng SF; Wang AR; Wang CF
Zhonghua Bing Li Xue Za Zhi; 2020 May; 49(5):448-453. PubMed ID: 32392928
[No Abstract] [Full Text] [Related]
100. The effects of passive anti-viral immunotherapy in AKR mice: II. Susceptibility to B cell lymphomagenesis.
Haran-Ghera N; Peled A; Canaani E; Caspi Y; Haimovich J; Shaft D; Resnitzky P; Brightman BK; Fan H
Leukemia; 1995 Nov; 9(11):1940-7. PubMed ID: 7475287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
